Becker's Healthcare September 23, 2021
Analyses have predicted that the use of biosimilar drugs could cut overall U.S. drug spending by more than $100 billion in the next five years, but many physicians are hesitant to switch patients from biologics to biosimilars, Kaiser Health News reported Sept. 23.
Biologic drugs are those made from living organisms, such as animal cells or bacteria. They’re more complex and expensive to make than drugs made out of chemicals, KHN reported.
Biosimilars are less expensive versions of biologic drugs that have no meaningful clinical differences from the biologic. An analysis from healthcare analytics company IQVIA cited by KHN found that in 2019, biologics accounted for 43 percent of drug spending in the U.S., and increased uptake of...
Today's Sponsors
Today's Sponsor